Re­gen­eron ex­pects key Dupix­ent COPD da­ta this year amid Eylea's sales de­cline in the US

One of the drug in­dus­try’s best-sell­ing ther­a­pies could be clos­er than ex­pect­ed to be­com­ing the first bi­o­log­ic to treat COPD, or chron­ic ob­struc­tive pul­monary dis­ease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER